Clinical Trials Logo

Hot Flushes clinical trials

View clinical trials related to Hot Flushes.

Filter by:

NCT ID: NCT03756272 Completed - Postmenopausal Clinical Trials

Stellate Ganglion Block to Reduce Hot Flushes

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus sham procedure

NCT ID: NCT03122301 Terminated - Hot Flashes Clinical Trials

Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer

Start date: June 1, 2017
Phase: Phase 2
Study type: Interventional

Vasomotor symptoms (hot flashes, night sweats, VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. VMS in Hispanic women are significantly more severe as compared to non-Hispanic Caucasian women. Few effective treatments for VMS are available, especially in the underserved Hispanic and Spanish-speaking populations which is problematic, as Hispanics will comprise 20% of the U.S. population by 2025. Stellate ganglion nerve block (SGB) with local anesthetic, previously performed for chronic pain indications, has shown promise as a potential treatment for menopausal women with VMS in previous clinical trials, but has not been investigated in Hispanic or Spanish-Speaking women with breast cancer in a controlled study.

NCT ID: NCT02907983 Suspended - Hot Flashes Clinical Trials

Stellate Ganglion Blockade in Post-Menopausal Women

R01
Start date: July 10, 2018
Phase: Phase 2
Study type: Interventional

Hot flashes and night sweats (vasomotor symptoms, VMS) affect 80% of women during the menopausal transition (MT). VMS are associated with decreased quality of life, increased depressive and anxiety symptoms, memory complaints, sleep disturbance, and reduced work productivity. Hormone therapy (HT) is highly effective in reducing VMS, but the use of HT declined 75% to 80% in the U.S. after the Women's Health Initiative (WHI) raised safety concerns about HT. In 2013, the Food and Drug Administration (FDA) approved paroxetine, a selective serotonin reuptake inhibitor (SSRI; 7.5 mg), as the first non-hormonal treatment for VMS. SSRIs are an important treatment option for many women, but their use in treating VMS is limited by lower effectiveness when compared to HT, side effects, and relapse of symptoms following treatment discontinuation. Identifying safe and effective non-hormonal treatments for VMS remains a priority in women's health research. Stellate ganglion blockade (SGB), used for decades in pain management, is a potential new approach to VMS treatment. Located in the cervical spine region, the stellate ganglia are part of the sympathetic nervous system. Although SGB is commonly performed to treat neuropathic pain, hyperhidrosis or vascular insufficiency, anatomic studies reveal connections between this ganglion and thermoregulatory regions of the brain, specifically the insular cortex. In this clinical trial, we aim to assess whether stellate ganglion block (SGB) with bupivacaine, a local anesthetic, is an effective and safe non-hormonal intervention for women seeking relief from vasomotor symptoms (VMS), and identify the physiologic mechanisms underlying SGB effects. Outcomes will include frequency and intensity of hot flashes, objectively-measured VMS, mood, quality of life, sleep, and memory performance in 160 postmenopausal women with 50 or more moderate to very severe hot flashes per week as measured by self-report for six months. They will be reassessed at 3 and 6 months following the SGB or a sham intervention for objective hot flashes and quality of life measures. Mechanistic outcomes (neuroimaging) will be obtained at baseline and 3 months following the intervention. Ambulatory monitoring of sympathetic nervous system function (SKNA) will be performed at baseline before the procedure, during the procedure and 1 hour following the procedure. This will be repeated at 2 and four weeks following the SGB or sham procedure for 1 hour recordings.

NCT ID: NCT02834312 Completed - Hot Flushes Clinical Trials

E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)

Start date: May 2016
Phase: Phase 2
Study type: Interventional

This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.

NCT ID: NCT02513329 Completed - Hot Flashes Clinical Trials

Stellate Ganglion Block (SGB) For Women for Breast Cancer

Start date: July 2015
Phase: Phase 2
Study type: Interventional

Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on anti-estrogens and are seeking relief from moderate to very severe VMS that are adversely affecting health and wellbeing. Women with breast cancer on Tamoxifen, aromatase inhibitors (AIs) or Selective Estrogen Receptor Modulators (SERMS) with moderate to very severe VMS will be enrolled as participants in this study.

NCT ID: NCT02028702 Completed - Osteoporosis Clinical Trials

Alternative Treatments for Menopausal Women

Start date: June 2012
Phase: N/A
Study type: Interventional

To investigate the reported health benefits (lipid profile, inflammatory factors, cardiovascular status and bone density) of a novel, phytoestrogen rich, Red Clover treatment on women suffering from both menopause related primary (hot flushes, night sweats, sleep disturbance and weight gain) and secondary (osteoporosis, cardiovascular and changes in lipid metabolism) symptoms.

NCT ID: NCT01816360 Completed - Menopause Clinical Trials

Aromatherapy and Yogatherapy for Hot Flashes

Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to verify and analyse psychological and physiological effects of olfactory aromatherapy and yogatherapy respiratory exercises, together and separately, on the quality of life, levels of stress, quality of sleep and intensity and frequence of hot flashes in climacteric women.

NCT ID: NCT01680900 Completed - Hot Flushes Clinical Trials

Vilazodone for Menopausal Hot Flashes

Start date: November 2012
Phase: N/A
Study type: Interventional

This is a pilot study to determine proof in principle that vilazodone, a selective serotonin reuptake inhibitor and 5HT1a agonist, reduces the frequency and severity of menopausal hot flashes relative to placebo. A secondary aim is to evaluate improvement in menopause-related quality of life.

NCT ID: NCT01466998 Completed - Hot Flashes Clinical Trials

Menopausal Treatment Using Relaxation Exercises (MaTURE)

MaTURE
Start date: January 2012
Phase: N/A
Study type: Interventional

Hot flashes occur in as many as two thirds of U.S. women during menopause and are severe enough to require treatment in 20%. Although postmenopausal hormone therapy is effective in suppressing hot flashes, it is associated with increased risk for a variety of serious adverse effects. There is an urgent need for alternative treatments that are effective, safe, and easy to use. In this study, the investigators will compare two different types of behavioral relaxation therapies, paced respiration and music therapy, for treatment of menopausal hot flashes. Effects on frequency of hot flashes, other symptom and quality-of-life outcomes associated with hot flashes, and physiologic measures of sympathetic/parasympathetic activity will be examined.

NCT ID: NCT01464697 Completed - Hot Flushes Clinical Trials

Progesterone for Perimenopausal Night Sweats

Start date: October 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether a oral micronized progesterone reduces the Vasomotor Symptom Score comprised of the number and severity of hot flushes and night sweats in perimenopausal women. Oral micronized progesterone is molecularly identical to human progesterone, a steroid hormone. It is sold by prescription for use to prevent endometrial cancer in women taking estrogen in menopause. This research study will test whether progesterone reduces perimenopausal hot flushes and night sweats. It will also test whether progesterone improves sleep disturbances and anxiety.